Pembrolizumab for Early Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. RESULTS: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improvement in overall survival has been reported in unresectable NSCLC patients and TNBC patients treated with anti PD-L1 antibody with chemotherapy”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Schmid et al., 2020
In the citing paper
“Immune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has shown promising results in TNBC4–6, but the overall response rate of ICB is less than 20%7.”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citation
Research works printed but not linked: 1
- Qi C Huang M Haiderali A et al. Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy. Presented at the NCCN Annual Conference Orlando March 21–23 2019.
Cited by
Items 101–200 of 1,004
What Is Known about Breast Cancer in Young Women?
Zhu, J. W., Charkhchi, P., Adekunte, S., & Akbari, M. R. (2023) · Cancers · doi:10.3390/cancers15061917 · Cited by 226
Heterogeneity within molecular subtypes of breast cancer
Turner, K. M., Yeo, S. K., Holm, T. M., Shaughnessy, E., & Guan, J. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00109.2021 · Cited by 197
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
Lee, J. S., Yost, S. E., & Yuan, Y. (2020) · Cancers · doi:10.3390/cancers12061404 · Cited by 180
The New Era of Immunotherapy in Gastric Cancer
Takei, S., Kawazoe, A., & Shitara, K. (2022) · Cancers · doi:10.3390/cancers14041054 · Cited by 176
Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future
Asaoka, M., Gandhi, S., Ishikawa, T., & Takabe, K. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420980377 · Cited by 191
Jin, M., Fang, J., Peng, J., Wang, X., Xing, P., Jia, K., Hu, J., Wang, D., Ding, Y., Wang, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02176-8 · Cited by 189
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 173
Santoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 153
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Tarantino, P., Corti, C., Schmid, P., Cortés, J., Mittendorf, E. A., Rugo, H. S., Tolaney, S. M., Bianchini, G., André, F., & Curigliano, G. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00386-1 · Cited by 164
Cardoso, F., O’Shaughnessy, J., Liu, Z., McArthur, H. L., Schmid, P., Cortés, J., Harbeck, N., Telli, M. L., Cescon, D. W., Fasching, P. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03415-7 · Cited by 186
“Additionally, pembrolizumab combined with neoadjuvant chemotherapy has been shown to improve pCR and EFS in patients with early-stage TNBC 9,10 .”
InfluentialRugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiß, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M. M., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab108 · Cited by 153
Yang, S., Shim, M. K., Kim, W. J., Choi, J., Nam, G., Kim, J., Kim, J., Moon, Y., Kim, H. Y., Park, J., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120791 · Cited by 147
Li, J., Chen, Y., Li, Y., Liu, N., & Ma, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01317-7 · Cited by 162
Novel targets for immune-checkpoint inhibition in cancer
Borgeaud, M., Sandoval, J. L., Obéid, M., Banna, G. L., Michielin, O. A., Addeo, A., & Friedlaender, A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102614 · Cited by 159
Localization, tissue biology and T cell state — implications for cancer immunotherapy
Schenkel, J. M., & Pauken, K. E. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00884-8 · Cited by 152
Bell, C. R., Pelly, V. S., Moeini, A., Chiang, S., Flanagan, E., Bromley, C. P., Clark, C. I., Earnshaw, C. H., Koufaki, M. A., Bonavita, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29606-9 · Cited by 149
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
Salomé, B., Sfakianos, J. P., Ranti, D. L., Daza, J., Bieber, C., Charap, A., Hammer, C., Banchereau, R., Farkas, A. M., Ruan, D. F., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.005 · Cited by 156
Versluis, J. M., Menzies, A. M., Sikorska, K., Rozeman, E. A., Saw, R. P. M., van Houdt, W. J., Eriksson, H., Klop, W. M. C., Ch’ng, S., van Thienen, J. V., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.004 · Cited by 152
Rizzo, A., Mollica, V., Tateo, V., Tassinari, E., Marchetti, A., Rosellini, M., Luca, R. D., Santoni, M., & Massari, F. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03366-x · Cited by 161
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 157
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Overview of recent advances in metastatic triple negative breast cancer
O'Reilly, D., AlSendi, M., & Kelly, C. M. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i3.164 · Cited by 162
Systemic therapy for early-stage breast cancer: learning from the past to build the future
Agostinetto, E., Gligorov, J., & Piccart, M. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00687-1 · Cited by 157
Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
Lee, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041524 · Cited by 158
“36), with no statistical difference [47].”
BackgroundProteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Anurag, M., Jaehnig, E. J., Krug, K., Lei, J. T., Bergstrom, E. J., Kim, B.-J., Vashist, T. D., Huynh, A. M. T., Dou, Y., Gou, X., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0200 · Cited by 147
“The programmed cell death receptor (PD1)–targeting antibody pembrolizumab is also approved for neoadjuvant TNBC treatment based on the results of the KEYNOTE-522 trial (6).”
BackgroundWang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 193
Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., Dupont, F., Rouas, G., Garcia, A. J., Craciun, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54145-w · Cited by 207
Allouchery, M., Lombard, T., Martin, M., Rouby, F., Sassier, M., Bertin, C., Atzenhoffer, M., Miremont‐Salamé, G., Pérault‐Pochat, M., & Puyade, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001622 · Cited by 144
Klement, J. D., Redd, P. S., Lu, C., Merting, A. D., Poschel, D. B., Yang, D., Savage, N. M., Zhou, G., Munn, D. H., Fallon, P. G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.005 · Cited by 141
Yang, R., Li, Y., Wang, H., Qin, T., Yin, X., & Ma, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00071-6 · Cited by 155
Huober, J., Barrios, C. H., Niikura, N., Jarząb, M., Chang, Y., Huggins-Puhalla, S. L., Pedrini, J. L., Zhukova, L., Graupner, V., Eiger, D., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02772 · Cited by 146
“Nonetheless, there is increasing evidence from neoadjuvant trials of early TNBC that PD-L1 status may not be a predictor of benefit from checkpoint inhibitor therapy in the early setting, and other additional factors, such as induction of an immune response or enrichment of TILs, may be more important.(29,33) In the p…”
BackgroundKumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 144
“Significant change is observed in both PD-L1 positive as well as negative TNBC patients where the rate of pCR change is higher in PD-L1 positive compared to the negative patient groups.(271) A phase 1 solid tumor study (JAVELIN) in which avelumab is used in metastatic TNBC having higher PD-L1 expression results in the…”
BackgroundResultMartini, R. N., Delpe, P., Chu, T. R., Arora, K. S., Lord, B., Verma, A., Bedi, D., Karanam, B., Elhussin, I. A., Chen, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0138 · Cited by 148
“Given our previous and current findings that uncover race–group differences in tumor immune responses, these findings have increasing relevance to overcome disparities, particularly in regard to the potential of immunotherapies to improve treatment response (24, 25).”
BackgroundNeoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
de Gooyer, P., Verschoor, Y. L., van den Dungen, L. D. W., Balduzzi, S., Marsman, H. A., Foppen, M. H. G., Grootscholten, C., Dokter, S., den Hartog, A. G., Verbeek, W. H. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03250-w · Cited by 151
Immunotherapy for early breast cancer: too soon, too superficial, or just right?
Franzoi, M. A., Romano, E., & Piccart, M. J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.022 · Cited by 138
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 145
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Catanzaro, E., Beltrán‐Visiedo, M., Galluzzi, L., & Krysko, D. V. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01245-8 · Cited by 150
Immunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A., Eggermont, A. M. M., & Galluzzi, L. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 123
“162,163 Perhaps the most significant results, however, have been achieved in patients with advanced dMMR/MSI ‐”
BackgroundLoi, S., Salgado, R., Curigliano, G., Díaz, R. I. R., Delaloge, S., García, C. I. R., Kok, M., Saura, C., Harbeck, N., Mittendorf, E. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03414-8 · Cited by 132
“Notably, whereas previous studies have shown that addition of programmed death 1 inhibition in TNBC led to small increases in pCR rates, including in patients with low PD-L1 expression, significant EFS benefit was observed 28,29 .”
Litton, J. K., Regan, M. M., Pusztai, L., Rugo, H. S., Tolaney, S. M., Garrett-Mayer, E. S., Amiri‐Kordestani, L., Basho, R. K., Best, A. F., Boileau, J.-F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00435 · Cited by 133
Barnestein, R., Galland, L., Kalfeist, L., Ghiringhelli, F., Ladoire, S., & Limagne, E. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2120676 · Cited by 124
“Regarding other therapeutics that act on the PI3K/AKT/mTOR pathway, we can also mention ipatasertib, which was initially evaluated in a phase III trial in combination with paclitaxel in patients with metastatic TNBC.149 This study was negative in terms of its primary endpoint, with no improvement in progression-free s…”
ResultInfluentialGarcía‐Recio, S., Hinoue, T., Wheeler, G. L., Kelly, B., Garrido-Castro, A. C., Pascual, T., de Cubas, A. A., Xia, Y., Felsheim, B., McClure, M. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00491-x · Cited by 193
Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
Li, Y., Zhan, Z., Yin, X., Fu, S., & Deng, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731535 · Cited by 140
Nielsen, D. L., Juhl, C. B., Chen, I. M., Kellermann, L., & Nielsen, O. H. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102440 · Cited by 136
Role of Tumor-Associated Myeloid Cells in Breast Cancer
Cha, Y. J., & Koo, J. S. (2020) · Cells · doi:10.3390/cells9081785 · Cited by 125
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Li, L., Zhang, F., Liu, Z., & Fan, Z. (2023) · Cancers · doi:10.3390/cancers15010321 · Cited by 135
“Moreover, PD-L1 status was found to be less predictive of efficacy in early-stage TNBC compared to late-stage disease, as discussed previously [55,60].”
BackgroundMethodResultSharma, P., Kimler, B. F., O’Dea, A. P., Nye, L. E., Wang, Y. Y., Yoder, R., Staley, J. M., Prochaska, L., Wagner, J. L., Amin, A. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3646 · Cited by 123
Singh, D. D., & Yadav, D. K. (2021) · Biomedicines · doi:10.3390/biomedicines9080876 · Cited by 124
Dieci, M. V., Guarneri, V., Tosi, A., Bisagni, G., Musolino, A., Spazzapan, S., Moretti, G., Vernaci, G. M., Griguolo, G., Giarratano, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2260 · Cited by 117
Tsvetkova, D. D., & Ivanova, S. A. (2022) · Molecules · doi:10.3390/molecules27082466 · Cited by 121
Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice
Winship, A., Alesi, L. R., Sant, S. A., Stringer, J. M., Cantavenera, A., Hegarty, T., Requesens, C. L., Liew, S. H., Sarma, U. C., Griffiths, M. J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00413-x · Cited by 121
Current Molecular Combination Therapies Used for the Treatment of Breast Cancer
Wang, Y., & Minden, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911046 · Cited by 151
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer
Agostinetto, E., Losurdo, A., Marta, G. N., Santoro, A., Punie, K., Barroso‐Sousa, R., POPOVIC, L. S., Solinas, C., Kok, M., de Azambuja, E., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2049232 · Cited by 114
“The low efficacy of ICIs as monotherapy in TNBC [26,27], and the increased activity observed with regimens combining ICIs with chemotherapy [36,40], suggest that treatment backbone might play an important role.”
BackgroundMethodInfluentialTriple negative breast cancer: approved treatment options and their mechanisms of action
Mandapati, A., & Lukong, K. E. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04189-6 · Cited by 133
Chen, L., Jiang, Y., Wu, S., Wu, J., Di, G., Liu, G., Yu, K., Fan, L., Li, J., Hou, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4313 · Cited by 117
“The inconsistent results may be related to the differentdrugsorinhibitionpathways,diseasestages(earlyratherthan late), PD-L1 assays, or all of these factors (19).”
Ditsch, N., Kolberg‐Liedtke, C., Friedrich, M., Jackisch, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., et al. (2021) · Breast Care · doi:10.1159/000516419 · Cited by 119
Shah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1110 · Cited by 105
Ahmed, F. S., Gaule, P., McGuire, J., Patel, K., Blenman, K., Pusztai, L., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1303 · Cited by 103
Rizzo, A., Cusmai, A., Acquafredda, S., Giovannelli, F., Rinaldi, L., Misino, A., & Palmiotti, G. (2022) · Future Oncology · doi:10.2217/fon-2021-1647 · Cited by 115
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
Mediratta, K., El‐Sahli, S., D’Costa, V. M., & Wang, L. (2020) · Cancers · doi:10.3390/cancers12123529 · Cited by 106
Zhao, Z., Fang, L., Xiao, P., Sun, X., Zhou, L., Liu, X., Wang, J., Wang, G., Cao, H., Zhang, P., et al. (2022) · Advanced Materials · doi:10.1002/adma.202205462 · Cited by 109
Gross, N. D., Miller, D. M., Khushalani, N. I., Divi, V., Ruiz, E. S., Lipson, E. J., Meier, F. E., Su, Y. B., Swiecicki, P. L., Atlas, J., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00459-x · Cited by 128
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
Santarpía, M., Aguilar, A., CHAIB-OUKADOUR, I., Cardona, A. F., Fancelli, S., Laguía, F., Bracht, J. W. P., Cao, P., Molina‐Vila, M. Á., Karachaliou, N., et al. (2020) · Cancers · doi:10.3390/cancers12061475 · Cited by 116
The changing role of natural killer cells in cancer metastasis
Chan, I. S., & Ewald, A. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci143762 · Cited by 114
Subphenotypes in acute kidney injury: a narrative review
Vaara, S. T., Bhatraju, P. K., Stanski, N. L., McMahon, B. A., Liu, K. D., Joannidis, M., & Bagshaw, S. M. (2022) · Critical Care · doi:10.1186/s13054-022-04121-x · Cited by 113
Cancer vaccines: current status and future directions
Zhou, Y., Wei, Y., Tian, X., & Wei, X. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01670-w · Cited by 135
“Worth mentioning, the FDA-approved standard treat-ment of pembrolizumab plus chemotherapy achieved 64% pathological CR and 84.5% 3-year event-free survival rate [178, 179].”
InfluentialYu, L., Liebenberg, K., Shen, Y., Liu, F., Xu, Z., Hao, X., Wu, L., Zhang, W., Chan, H. L., Wei, B., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.002 · Cited by 120
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy
Marra, A., & Curigliano, G. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000498 · Cited by 112
Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesis
Xiao, J. M., Rahbar, H., Hippe, D. S., Rendi, M. H., Parker, E. U., Shekar, N., Hirano, M., Cheung, K. J., & Partridge, S. C. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00247-3 · Cited by 111
Pingili, A. K., Chaib, M., Sipe, L. M., Miller, E. J., Teng, B., Sharma, R., Yarbro, J. R., Asemota, S., Abdallah, Q. A., Mims, T. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109285 · Cited by 104
Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
Long, G. V., Menzies, A. M., & Scolyer, R. A. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02575 · Cited by 109
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
Smith, S. M., WACHTER, K., Burris, H. A., Schilsky, R. L., George, D. J., Peterson, D. E., Johnson, M. L., Markham, M. J., Mileham, K. F., Beg, M. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03420 · Cited by 115
Tarantino, P., Gandini, S., Trapani, D., Criscitiello, C., & Curigliano, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103223 · Cited by 105
The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
Leon-Ferre, R. A., Hieken, T. J., & Boughey, J. C. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09480-9 · Cited by 109
Subhan, M. A., Parveen, F., Shah, H., Yalamarty, S. S. K., Ataide, J. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15082204 · Cited by 118
“More recently, in 2021, the accelerated approval for pembrolizumab became a routine approval, and the FDA also granted pembrolizumab approval as a neoadjuvant for high-risk, early-stage non-metastatic TNBC in combination with chemotherapy and as a monotherapy in adjuvant treatment based on a Keynote-522 (NCT03036488)…”
BackgroundMolecular Classification of Breast Cancer
Roy, M., Fowler, A. M., Ulaner, G. A., & Mahajan, A. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.04.002 · Cited by 118
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
Garutti, M., Lambertini, M., & Puglisi, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100276 · Cited by 119
Wu, S., Xu, Y., Chen, L., Fan, L., Ma, X.-Y., Zhao, S., Song, X.-Q., Hu, X., Yang, W.-T., Chai, W.-J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01536-6 · Cited by 102
Supervised discovery of interpretable gene programs from single-cell data
Kunes, R., Walle, T., Land, M., Nawy, T., & Pe’er, D. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01940-3 · Cited by 116
“3b), yet the absence of tumor-reactive, non-terminally exhausted states in responders is inconsistent with the treatment-induced clonal expansion of these states 19,20,24,25 , and it conflicts with the proven efficacy of ICT in this clinical setting 26 .”
Ericsson, P. I. G., Wulfkhule, J. D., Gallagher, R. I., Sun, X., Axelrod, M. L., Sheng, Q., Luo, N., Gómez, H., Sanchez, V. M., Sanders, M. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0607 · Cited by 92
Immunotherapy toxicity: identification and management
Gumusay, O., Callan, J., & Rugo, H. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06480-5 · Cited by 101
The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas
Annaratone, L., Cascardi, E., Vissio, E., Sarotto, I., Chmielik, E., Sapino, A., Berrino, E., & Marchiò, C. (2020) · Pathobiology · doi:10.1159/000507055 · Cited by 104
Derouane, F., van Marcke, C., Berlière, M., Gerday, A., Fellah, L., Leconte, I., Bockstal, M. V., Galant, C., Corbet, C., & Duhoux, F. P. (2022) · Cancers · doi:10.3390/cancers14163876 · Cited by 104
“In addition, PDL1-positive patients had a higher rate of pCR in both arms [81].”
BackgroundGuo, X., Nie, H., Zhang, W., Li, J., Ge, J., Xie, B., Hu, W., Zhu, Y., Zhong, N., Zhang, X., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.001 · Cited by 100
Wu, S.-Y., Xiao, Y., Wei, J., Xu, X., Jin, X., Hu, X., Li, D., Jiang, Y., & Shao, Z.-M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002528 · Cited by 100
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
Wong, W., Brogi, E., Reis-Filho, J. S., Plitas, G., Robson, M. E., Norton, L., Morrow, M., & Wen, H. Y. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00302-z · Cited by 98
Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024
Li, J., Hao, C., Wang, K., Zhang, J., Chen, J., Liu, Y., Nie, J., Yan, M., Liu, Q., Geng, C., et al. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-31 · Cited by 116
“Moreover, continuing to use PD-1 inhibitors following surgery had a beneficial effect on EFS (9).”
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply.
Schmid, P., Dent, R. A., & O’Shaughnessy, J. (2020) · PubMed · doi:10.1056/nejmc2006684 · Cited by 36
Boman, C., Zerdes, I., Mårtensson, K., Bergh, J. C. S., Foukakis, T., Valachis, A., & Matikas, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102257 · Cited by 98
Platinum-based systematic therapy in triple-negative breast cancer
Zhu, Y., Hu, Y., Tang, C., Guan, X., & Zhang, W. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188678 · Cited by 104
Presti, D., Dall’Olio, F. G., Besse, B., Ribeiro, J. M., Meglio, A. D., & Soldato, D. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103773 · Cited by 99
Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer
Loap, P., Loirat, D., Berger, F., Rodrigues, M. J., Bazire, L., Pierga, J., Vincent‐Salomon, A., Laki, F., Boudali, L., Raizonville, L., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5074 · Cited by 100
Røssevold, A. H., Andresen, N. K., Bjerre, C. A., Gilje, B., Jakobsen, E. H., Raj, S. X., Falk, R. S., Russnes, H. G., Jahr, T., Mathiesen, R. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02126-1 · Cited by 89
Goddard, E. T., Linde, M. H., Srivastava, S., Klug, G., Shabaneh, T. B., Iannone, S., Grzelak, C. A., Marsh, S. A., Riggio, A. I., Shor, R. E., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.011 · Cited by 107
Zhang, X., Goedegebuure, S. P., Chen, M. Y., Mishra, R., Zhang, F., Yu, Y. Y., Singhal, K., Li, L., Gao, F., Myers, N. B., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01388-3 · Cited by 98
Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
Loizides, S., & Constantinidou, A. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1095839 · Cited by 103
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
“In the ongoing NCT03036488 study, carried out on early TNBC patients, the percentage of a pathological complete response was considerably higher among patients who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy [276].”
BackgroundKüemmel, S., Heil, J., Bruzas, S., Breit, E., Schindowski, D., Harrach, H., Chiari, O., Hellerhoff, K., Bensmann, E., Hanf, V., et al. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.1772 · Cited by 92
Meattini, I., Becherini, C., Caini, S., Coles, C. E., Cortés, J., Curigliano, G., de Azambuja, E., Isacke, C. M., Harbeck, N., Kaidar‐Person, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00534-x · Cited by 99
Cancer vaccines and the future of immunotherapy
Pail, O., Lin, M. J., Anagnostou, T., Brown, B. D., & Brody, J. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00553-7 · Cited by 116
Metadata
- Authors
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., Dent, R., & O’Shaughnessy, J.
- Affiliations
- Queen Mary University of London (GB)
- IOB Institute of Oncology, Quiron Group;Vall d’Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain
- Yale Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Kliniken Essen-Mitte (DE)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Samsung Medical Center (KR)
- The University of Sydney (AU)
- Ludwig-Maximilians-Universität München (DE)
- Sapporo National Hospital (JP)
- Universitätsklinikum Erlangen (DE)
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Helios Hospital Berlin-Buch (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National University of Singapore (SG)
- Baylor University Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 810-821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3006930853
- Cited by
- 3,270
- References
- 31
- Citations by year
- 2026: 580 · 2025: 576 · 2024: 552 · 2023: 500 · 2022: 514 · 2021: 391 · 2020: 152
- FWCI
- 133.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pembrolizumab, triple-negative breast cancer, early breast cancer, neoadjuvant immunotherapy, neoadjuvant chemotherapy, paclitaxel, carboplatin, pathological complete response, event-free survival, immune checkpoint inhibitors, doxorubicin-cyclophosphamide, epirubicin-cyclophosphamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Middle Aged, Neoplasm Staging, Epirubicin, Carboplatin, Paclitaxel, Neoadjuvant Therapy, Kaplan-Meier Estimate, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.